Management challenges for chronic dysimmune neuropathies during the COVID ‐19 pandemic-Reference-Cited by-同舟云学术

Management challenges for chronic dysimmune neuropathies during the COVID ‐19 pandemic

Published:2020-04-24 Issue:1 Volume:62 Page:34-40
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle & Nerve

Author:

Rajabally Yusuf A.¹²,Goedee H. Stephan³,Attarian Shahram⁴⁵,Hartung Hans‐Peter⁶

Affiliation:

1. Inflammatory Neuropathy Clinic University Hospitals Birmingham Birmingham United Kingdom

2. Aston Medical School Aston University Birmingham United Kingdom

3. Brain Center Rudolf Magnus, Department of Neurology and Neurosurgery University Medical Center Utrecht Heidelberglaan 100, 3584 CX, Utrecht The Netherlands

4. Reference Centre for Neuromuscular Diseases and ALS Centre Hospitalier Universitaire La Timone 264 rue Saint‐Pierre, 13385, Marseille France

5. Aix‐Marseille University Inserm, GMGF, Marseille France

6. Department of Neurology, Medical Faculty and Center of Neurology and Neuropsychiatry LVR Klinikum, Heinrich‐Heine University Düsseldorf Germany

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Clinical Neurology,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.26896

Reference42 articles.

1. On being a neurologist in Italy at the time of the COVID-19 outbreak

2. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP

3. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher

4. AANEM.Guidance for Managing NCS/EMG Testing Requests During COVID‐19. AANEM March 31 2020.

5. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physical Activity in Patients with Neuromuscular Disease Three Years after COVID-19, a Longitudinal Survey: The After-Effects of the Quarantine and the Benefits of a Return to a Healthier Life-Style;Journal of Clinical Medicine;2024-01-03

2. Current clinical management of CIDP with immunoglobulins in France: An expert opinion;Revue Neurologique;2023-10

3. Reduction of Infusion Time Using a 10% Intravenous Immunoglobulin Formulation With a 15-Minute Rate Escalation Protocol During Staffing Shortages Due to COVID-19;Journal of Infusion Nursing;2022-11

4. A Scoping Review of Barriers and Facilitators Affecting the Lives of People With Disabilities During COVID-19;Frontiers in Rehabilitation Sciences;2022-01-25

5. Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study;Reviews in Medical Virology;2021-10-26